NYSE:PBHPharmaceuticals
Prestige Consumer Healthcare (PBH) Stock Could Be 30.1% Undervalued After Weak Earnings And Guidance
Prestige Consumer Healthcare (PBH) is back in focus after fiscal 2026 earnings missed estimates, revenue declined year over year, and guidance for fiscal 2027 came in below consensus expectations.
See our latest analysis for Prestige Consumer Healthcare.
Those weaker fiscal 2026 results, cautious fiscal 2027 guidance, and the new investor investigation have coincided with a sharp loss of momentum, with Prestige Consumer Healthcare’s share price down 25.1% over 90 days and its 1 year total...